• Explore /
  • Poster
  • / A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer.

A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer.

Abstract Poster

Authors

null

Phillip Lee Palmbos

University of Michigain Health System, Ypsilanti, MI

Phillip Lee Palmbos , Felix Yi-Chung Feng , Scott A. Tomlins , William Kevin Kelly , Alicia Katherine Morgans , Mary-Ellen Taplin , Neeraj Agarwal , Emmanuel S. Antonarakis , Przemyslaw Twardowski , Jon Jacobson , Matthew S. Davenport , Stephanie Daignault , Karen E. Knudsen , Maha Hussain

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer

Sub Track

Prostate Cancer

Clinical Trial Registration Number

NCT02059213

Citation

J Clin Oncol 33, 2015 (suppl; abstr TPS5074)

DOI

10.1200/jco.2015.33.15_suppl.tps5074

Abstract #

TPS5074

Poster Bd #

65b

Abstract Disclosures

Similar Posters

Poster

2017 Genitourinary Cancers Symposium

Feasibility of cotargeting cell cycle and androgen signaling in metastatic hormone-sensitive prostate cancer (mHSPC).

Feasibility of cotargeting cell cycle and androgen signaling in metastatic hormone-sensitive prostate cancer (mHSPC).

First Author: Phillip Lee Palmbos

First Author: Phillip Lee Palmbos

First Author: Phillip Lee Palmbos

First Author: Bridget F. Koontz